Characteristics, outcomes and treatment patterns in acute myeloid leukemia patients 60 years or older in Colombia: a RENEHOC-PETHEMA study
Authors:
- Claudia Sossa-MeloCSClaudia Sossa-Melo
- Virginia Abello-PoloVAVirginia Abello-Polo
- Luis A. SalazarLSLuis A. Salazar
- Angela M. PeñaAPAngela M. Peña
- María Luna-GonzálezMLMaría Luna-González
- Diana Cuervo-LozadaDCDiana Cuervo-Lozada
- Guillermo E. Quintero-VegaGQGuillermo E. Quintero-Vega
- Jorge DazaJDJorge Daza
- Olga Paola Omaña-OrduzOOOlga Paola Omaña-Orduz
- William MantillaWMWilliam Mantilla
- Iván PerdomoIPIván Perdomo
- Kenny GalvezKGKenny Galvez
Open Access
- 16 January 2025
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (1) , 369-381
Abstract
There is a limited information available on the clinical characteristics, treatment patterns and outcomes on older patients diagnosed with Acute Myeloid Leukemia (AML) in Latin-America. This multicenter retrospective study analyzed 269 patients over 60 years of age diagnosed with AML in Colombia, using data from RENEHOC-PETHEMA registry, from 2009 to 2023. The median age at diagnosis was 70 years (Range:60–98), 55% were men, 61% had an ECOG < 2, and 75.5% had de novo AML. FLT3-ITD or NPM1 mutations were performed in 23.4% and 15.6% patients, and detected in 14.3% and 16.7% of cases, respectively. Treatment included intensive chemotherapy (IC) (36.8%), Low-Intensity Regimen Based on Low-Dose Cytarabine (LDAC-based) (12.6%), hypomethylating agents (HMAs, with/without venetoclax) (35.3%), and supportive care (15.2%). The overall survival (OS) rate was 35.2% at 1 year and 5.6% at 5 years (13.7% for IC, 9.4% for LDAC-based, and 0% for other treatments); with median OS of 8.2 months (10.6 months after IC, 8.8 months after non-IC, 8.9 months after azacitidine/decitabine, 8.2 months after azacitidine-venetoclax, and 1.9 months with supportive care). Only 1.5% of patients underwent a transplant in the first line. The Leukemia-free survival (LFS) rate was 45.8% at 1-year and 13.7% at 5-years (22.4% for IC, 9.4% and 0% for other treatments); with median LFS of 9.5 months (17.3 months after IC, 7.4 months after LDAC-based, and 10.8 months after HMA). This study provides new insights into the management of patients in Colombia, highlighting the need for a highly individualized approach in treating AML in elderly patients.Keywords
All Related Versions
This publication has 24 references indexed in Scilit:
- Outcomes and survival predictors of Latin American older adults with acute myeloid leukemia: Data from a single centerHematology, Transfusion and Cell Therapy, 2022
- Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registriesLeukemia, 2021
- Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AMLBlood, 2020
- Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemiaHaematologica, 2019
- A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agentLeukemia Research, 2019
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemiaBlood, 2019
- Acute myeloid leukemia: 2019 update on risk‐stratification and managementAmerican Journal of Hematology, 2018
- Selecting initial treatment of acute myeloid leukaemia in older adultsBlood Reviews, 2017
- Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia RegistryBlood, 2009
- The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trialBlood, 2001